Time-Restricted Eating on Appetite and Inflammation in Adults With Obesity and Prediabetes: A Randomized Feeding Study.

Obesity (Silver Spring)Jul 27, 2026 (epub)
Clinical ResearchEndocrinologyInternal Medicine (General)Open access

Daisy Duan, Susan Carnell, Scott J Pilla et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined the effects of 10-hour time-restricted eating (TRE) versus a 16-hour usual eating pattern (UEP) on appetite and inflammation in 39 adults with obesity and prediabetes or diet-controlled type 2 diabetes over 12 weeks. Both groups experienced similar weight loss (2.7% TRE vs 2.5% UEP) and improvements in eating behavior, with no significant differences in appetite hormones or inflammatory markers.

Key findings

  • Weight loss was similar between TRE (2.7%) and UEP (2.5%) groups.
  • Both groups showed increased restraint and decreased disinhibition and hunger.
  • No significant between-group differences in appetite hormones or inflammatory markers were observed.

Why it matters

Understanding the impact of time-restricted eating on appetite and inflammation can inform dietary recommendations for patients with obesity and prediabetes, potentially aiding in weight management and metabolic health.

Source

PubMed · PMID 42508996Free full text on PubMed Central

Published in Obesity (Silver Spring). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.